COVID-19's nucleic acid detection technology is mainly divided into two categories: non-invasive and invasive, among which, in COVID-19 detection, the kit is the core, accounting for 80%. According to the data of official website Health and Health Commission, as of May 2020, there were 3 1 7500 confirmed cases in COVID-19. Among them, the number of confirmed cases in Wuhan was 1.42 million (including 4 cases of asymptomatic infection1.00 million). Compared with 20 19, the number of new cases in Wuhan decreased by 74%[ 1]. So the outbreak of the COVID-19 epidemic allowed the COVID-19 test to enter? Run away? Stage. ?
COVID-19 is a new virus. It will not infect people specifically in human body, but it will spread from person to person. After COVID-19 is infected, there will be symptoms such as fever, cough and expectoration in the early stage, which is difficult to be diagnosed by medical means, and even viral nucleic acid detection is needed. The emergence of COVID-19 epidemic has brought opportunities and challenges to the detection industry in COVID-19. The characteristics of COVID-19's rapid spread and wide spread make the prevention and control of epidemic situation in China face severe challenges. In order to improve the efficiency and accuracy of epidemic prevention and control in China, and control the epidemic spread speed, the comprehensive group of joint prevention and control mechanism in the State Council requested medical institutions to strengthen COVID-19 nucleic acid detection?
At present, the nucleic acid detection market is dominated by foreign enterprises, and there are few domestic enterprises. Foreign giants have rich scientific research experience and technical reserves in the field of nucleic acid detection, and the core technologies such as nucleic acid detection equipment and reagents are independently developed. According to the data of Illumina official website, the United States and Canada mainly form nucleic acid detection business through acquisition, technical cooperation, self-research and agency, among which self-developed products account for a relatively high proportion. In terms of product types, NGS and PCR kits account for more than 90% (more than 80% in the United States), and the rest are mainly nucleic acid extraction reagents, PCR kits and supporting reagents.